GlassScriptPhysician profile
Julie A Biller
NPI 1619928066
$52,386.91
in general payments reported to CMS, 2019-2025
23 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $8,814 · 2021: $5,782 · 2022: $220 · 2023: $214 · 2024: $99.43 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,416 · Food and Beverage: $885 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,416.18 |
| Food and Beverage | $885.20 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37,820.84 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $6,855.40 | 2019-2025 | Trikafta |
| Abbvie INC. | $5,097.41 | 2019-2023 | Creon |
| Insmed, INC. | $1,487.50 | 2020-2025 | Brinsupri |
| United Therapeutics Corporation | $219.09 | 2023-2025 | |
| Baxter Healthcare | $209.34 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Astrazeneca Pharmaceuticals LP | $149.44 | 2025 | Fasenra |
| Nestle Healthcare Nutrition INC. | $79.65 | 2022-2023 | |
| Electromed, INC. | $76.14 | 2023-2024 | Smartvest |
| Mylan Specialty L.P. | $66.67 | 2019-2022 | |
| Philips North America LLC | $61.42 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Advanced Respiratory, INC | $57.92 | 2020-2021 | |
| Vivus LLC | $36.79 | 2021-2022 | |
| Amgen INC. | $34.00 | 2025 | |
| Chiesi USA, INC. | $31.22 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $31.14 | 2025 | Tobi Podhaler |
| Genentech USA, INC. | $28.21 | 2021-2022 | |
| Glaxosmithkline, LLC. | $19.00 | 2025 | Nucala |
| Aimmune Therapeutics, INC. | $13.70 | 2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $12.03 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Biller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.